




Ovarian cancer (OC) is often diagnosed at later stages, resulting in poor prognosis for patients.¹ Epithelial ovarian cancer (EOC) has 5 major histotypes exhibiting a large degree of heterogeneity.² FR α expression is a prognostic biomarker that is more prevalent in patients with high-grade, serous histology.^{3,4}

Epithelial Ovarian Cancer²



Analyzing biomarkers could help improve disease detection and evaluation of treatment responses.^{2,5}

FRα and HER2 are protein biomarkers that are expressed in EOCs, with differential expression across histotypes.³⁻⁹

Protein Biomarker	FRα	HER2
Expression in OC	≤90% ⁵	~7–39% ⁶
Prevalence Across Histotypes	More prevalent in patients with HGSC ^{3,4}	Differs across histotypes and studies ^{7,8}
Expression Consistency in Select Studies	Retained in ~88% of recurrent tumors following chemotherapy ^{3,10}	Increased in ~58% of time-lagged biopsies and following OC treatment ^{7*}

*The treatment of this study contained both platinum-based chemotherapy and poly (ADP-ribose) polymerase inhibitors.
EOC=epithelial ovarian cancer; FRα=folate receptor alpha; HER2=human epidermal growth factor receptor 2; HGSC=high-grade serous carcinoma; OC=ovarian cancer.

Biomarker prevalence and expression consistency estimates are based on multiple sources, including small, single-center studies. Data can vary among studies and data sets because of detection methodologies, modalities, and reagents as well as patient sample sizes and/or demographics/characteristics. Some biomarkers may overlap.

References: 1. SEER Cancer Stat Facts: Ovarian Cancer. National Cancer Institute. Bethesda, MD. seer.cancer.gov/statfacts/html/ovary.html. 2. López-Portugués C, Montes-Bayón M, Díez P *Proteomes*. 2024;12(1):8. 3. Kalli KR, Oberg AL, Keeney GL, et al. *Gynecol Oncol*. 2008;108(3):619-626. 4. Köbel M, Madore J, Ramus SJ, et al. *Br J Cancer*. 2014;111(12):2297-2307. 5. Bax HJ, Chauhan J, Stavraka C, et al. *Br J Cancer*. 2023;128(2):342-353. 6. Serrano-Olvera A, Dueñas-González A, Gallardo-Rincón D, Candelaria M, De la Garza-Salazar J. *Cancer Treat Rev*. 2006;32(3):180-190. 7. Kim YN, Chung YS, Park E, Lee ST, Lee JY. *Sci Rep*. 2024;14(1):7992. 8. Verri E, Guglielmini P, Puntoni M, et al. *Oncology*. 2005;68(2-3):154-161. 9. Crane LMA, Arts HJG, van Oosten M, et al. *Cell. Oncol*. 2011;35(1):9-18.